July 15, 2016 - Orgenesis, Inc. (NASDAQ:ORGS) has filed a financial statement reporting Weighted Average Number Of Shares Outstanding Basic of $107,583,871,000 USD. Previously, on October 14, 2016, Orgenesis, Inc. reported Weighted Average Number Of Shares Outstanding Basic of $111,188,616 USD. This represents a change of 96,657.99% in Weighted Average Number Of Shares Outstanding Basic.

Period EndPeriodValue
2016-05-31 2016-Q2 107,583,871,000
2016-08-31 2016-Q3 111,188,616
2017-02-28 2017-Q1 9,285,429
2016-02-29 2016-Q1 103,127,025
2015-08-31 2015-Q3 55,835,950
2015-05-31 2015-Q2 55,785,407
2015-02-28 2015-Q1 55,735,394
2014-08-31 2014-Q3 54,916,980
2014-05-31 2014-Q2 54,010,496
2014-02-28 2014-Q1 52,085,973
2017-05-31 2017-Q2 114,820,844,000
2017-08-31 2017-Q3 123,349,597
2018-02-28 2018-Q1 10,775,877
CostOfRevenue DeferredRevenueCurrent GeneralAndAdministrativeExpense IncomeTaxExpenseBenefit IncreaseDecreaseInDeferredRevenue IncreaseDecreaseInPrepaidExpense InterestExpenseShortTermBorrowings OtherNonoperatingIncomeExpense PrepaidExpenseCurrent ResearchAndDevelopmentExpense Revenues ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroMbrFourRynTkMKW ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroNKyFourtrSbNEightcT ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroOnenFivedvBmbCPZerob ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroQJEightQHEightvKrPTQ ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroSixVScnTyThreeEightTNX ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroSrrhxFiveEightxbQlSeven ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroTHSevenFkNTWyFourCJ ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroTwoFivefSixggwbHLHk ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroVpvvmTwoFiveHMcck ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroZpQmcvvcRzmFour ScheduleOfFinancialExpensesZeroThreeEightFourZeroZerohdRbGVtSixGOneWh ScheduleOfFinancialExpensesZeroThreeEightFourZeroZerozHFouryNxKThreeFFourGb ScheduleOfIntangibleAssetsFutureAmortizationExpenseZeroThreeEightFourZeroZeroFourGqHKpPHOnevrG ScheduleOfIntangibleAssetsFutureAmortizationExpenseZeroThreeEightFourZeroZerobTsKmSevenvVKScB ScheduleOfResearchAndDevelopmentExpensesZeroThreeEightFourZeroZeroFourLMfQFcMBTXZero ScheduleOfResearchAndDevelopmentExpensesZeroThreeEightFourZeroZeroddPFTwolPmTSixHN ScheduleOfResearchAndDevelopmentExpensesZeroThreeEightFourZeroZerofpdTgJEightdrKRS ScheduleOfResearchAndDevelopmentExpensesZeroThreeEightFourZeroZerolDpQDOneTZeroFMTwoNine ScheduleOfResearchAndDevelopmentExpensesZeroThreeEightFourZeroZeroshmKPlBDJbtFour ScheduleOfResearchAndDevelopmentExpensesZeroThreeEightFourZeroZerovGLmQlmNSixZerokT ScheduleOfResearchAndDevelopmentExpensesZeroThreeEightFourZeroZeroxZtEighttqXtPlFV ScheduleOfRevenueZeroThreeEightFourZeroZeroEightNineXwREightzvFiveThreeTd ScheduleOfRevenueZeroThreeEightFourZeroZeroEightwpCFourTwomFFourhgEight ScheduleOfRevenueZeroThreeEightFourZeroZeroKcwVnhZeroNzMtFour ScheduleOfRevenueZeroThreeEightFourZeroZerotttPFiveZRhCOneJr ScheduleOfRevenueZeroThreeEightFourZeroZeroyfmEightcBSMkcgFive ScheduleOfRevenueZeroThreeEightFourZeroZerozMThreeSixFkqmgSsR ScheduleOfRevenuesFromMajorCustomersZeroThreeEightFourZeroZeroTJtWLZNZClFk ScheduleOfRevenuesFromMajorCustomersZeroThreeEightFourZeroZeroTSevenMKgxCThreeWFourDFour ScheduleOfRevenuesFromMajorCustomersZeroThreeEightFourZeroZeroTwoNNinexFivegWDTRsl ScheduleOfRevenuesFromMajorCustomersZeroThreeEightFourZeroZeroXlsBMSevenvEightOnenrM ScheduleOfRevenuesFromMajorCustomersZeroThreeEightFourZeroZerofKFivexOneFiveybTfps ScheduleOfRevenuesFromMajorCustomersZeroThreeEightFourZeroZeroxTwoNqFourrgKbJFourThree StockBasedCompensationExpensesRelatedToOptionsGrantedToEmployeesAndDirectors

Related News Stories

Orgenesis, Inc. - Overlooked Stock In The Gene Therapy Contract Development With R&D Pipeline

2018-06-03 seekingalpha
Overlooked specialty contract development and manufacturing stock in the exciting field of advanced cell therapy with a potential for an exponential upside. (184-3)

CUSIP: 68619K105